LACOG 0419 – NEOSAMBA | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer OPEN FOR RECRUITMENT
LACOG 0721 – Cherry Pick | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients with HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade – CHERRY-PICK TRIAL (LACOG 0721)
LACOG 0115 – LORELEI | A Phase II Randomized, Double-Blind, Parallel Cohort Study of Neoadjuvant Letrozole + GDC-0032 versus Letrozole + Placebo in Post-Menopausal Women with ER+/HER2- Primary Breast Cancer.
LACOG 0715 – PALLAS | A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer
LACOG 0801 – GLICO | A randomized open-label, phase II study of lapatinib/capecitabine or lapatinib/vinorelbine or lapatinib/gemcitabine in subjects with Her2/neu amplified metastatic breast cancer patients progressing after taxanes treatment.
LACOG 2118 – ALEXANDRA/IMpassion 030 | A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.
LACOG 0218 – Hercules | A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer
LACOG 0519 – PEACE III | A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
LACOG 0522 – DORA | DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC). OPEN FOR RECRUITMENT
LACOG 0620 – ExBAT | Extreme Bipolar Androgen Therapy with Darolutamide and Testosterone Cypionate in Patients with Metastatic Castration-Resistant Prostate Cancer (ExBAT trial)
LACOG 0415 – APA in Prostate Cancer | Phase II randomized study of Abiraterone acetate plus ADT versus APALUTAMIDE versus Abiraterone and APALUTAMIDE in patients with advanced prostate cancer with non-castrate testosterone levels
LACOG 0223 / GOG-3073 – ROSELLA | A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian Primary Peritoneal, or Fallopian-Tube Cance
LACOG 0623 – eVOLVE-Cervical | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) OPEN FOR RECRUITMENT
LACOG 0920 – Senticol III | International Validation Study Of Sentinel Node Biopsy In Early Cervical Cancer
LACOG 1018 – PALBO in Ovarian Cancer | Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer
LACOG 0720 – SMART-KEY | SMART-KEY: A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers
LACOG 0318 – Induction | Randomized, Open-label, Phase III Trial of Induction Chemotherapy Followed by Chemoradiotherapy versus Upfront Chemoradiotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma
LACOG 0821 – AMIGO-1 | A single arm, phase 2 study of amivantamab, lazertinib and pemetrexed for first-line treatment of recurrent / metastatic non-small cell lung cancers (NSCLCs) with EGFR mutations
LACOG 2218 – PACIFIC BRAZIL | Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL)
LACOG 0211 – ALK | A clinical and epidemiologic study of EML4-ALK and other ALK fusions genes in lung cancer patients in Latin American.
LACOG 0618 | Safety and Efficacy of Nivolumab in previously treated patients with advanced NSCLC: Real World Data from an Expanded Access Program in Brazil
LACOG 0213 – AUGMENT | A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/RefractoryIndolent Lymphoma.
LACOG 0214 – FINEP | Validation of 99mTc- EDDA – HYNIC -TOC kits for diagnosis of neuroendocrine tumors
